Document:

exv10w26

Exhibit 10.26

CONFIDENTIAL TREATMENT REQUESTED

COMMERCIAL CONTRACT MANUFACTURING AGREEMENT

Dated as of

February 5, 2010

By and Between

Alimera Sciences, Inc.

And

Alliance Medical Products, Inc.

 

 

CONFIDENTIAL TREATMENT REQUESTED

COMMERCIAL CONTRACT MANUFACTURING AGREEMENT

This COMMERCIAL CONTRACT MANUFACTURING AGREEMENT (this “AGREEMENT”), dated as of February 5, 2010
(the “EFFECTIVE DATE”), by and between Alimera Sciences, Inc., a Delaware corporation (“CUSTOMER”),
with offices at 6120 Windward Parkway, Suite 290, Alpharetta, GA 30005 and Alliance Medical
Products, Inc., (“AMP”), a California corporation, with offices at 9342 Jeronimo Rd., Irvine, CA
92688.

WITNESSETH:

WHEREAS, CUSTOMER has disclosed KNOW-HOW (as defined below) to AMP in order to enable AMP to
MANUFACTURE
PRODUCT(S) (as defined below) for CUSTOMER; and

WHEREAS, CUSTOMER desires AMP to MANUFACTURE PRODUCT(S) for CUSTOMER in accordance with the terms
and conditions set forth in this AGREEMENT; and

WHEREAS, AMP has appropriate facilities and the ability to MANUFACTURE PRODUCT(S), and is willing
to MANUFACTURE PRODUCT(S) for CUSTOMER, in accordance with the terms and conditions set forth in
this AGREEMENT;

NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the parties
hereto agree as follows:

1.0     DEFINITIONS

The following terms as used in this AGREEMENT shall have the meanings set forth in this
Section:

	 	1.1	 	The term “AFFILIATE” means (1) any corporation or business entity fifty percent (50%) or
more of the voting stock or voting equity interests of which are owned directly or
indirectly by the applicable party; or (2) any corporation or business entity which directly
or indirectly owns fifty percent (50%) or more of the voting stock or voting equity
interests of the applicable party; or (3) any corporation or business entity directly or
indirectly controlling or under control of a corporation or business entity as described in
(1) or (2), in each case, only for so long as such ownership or control continues to exist.
	 
	 	1.2	 	The term “AGENCY” means any applicable local, state or national regulatory authority in
the United States and other applicable regulatory authorities outside the United States
involved in granting approvals for the MANUFACTURING of PRODUCT(S).
	 
	 	1.3	 	The term “ANNUAL CHARGES” means the costs associated with the maintenance of the
validations needed to MANUFACTURE the PRODUCT(S), as specified in ATTACHMENT 6.1.
	 
	 	1.4	 	The term “AMP EQUIPMENT” means all equipment and machinery owned by AMP and used directly
or indirectly to MANUFACTURE PRODUCT(S). For the avoidance of doubt, AMP EQUIPMENT shall
not include CUSTOMER EQUIPMENT.
	 
	 	1.5	 	The term “AMP INTELLECTUAL PROPERTY” shall have the meaning set forth in the definition
of KNOW-HOW in the AGREEMENT.
	 
	 	1.6	 	The term “API” means the Active Pharmaceutical Ingredient, as supplied by the CUSTOMER
for use in MANUFACTURING the PRODUCT(s).
	 
	 	1.7	 	The term “CALENDAR YEAR” means any period during the TERM commencing on January 1 and
ending on December 31.

- 2 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	1.8	 	The term “cGMPs” means all laws and regulations relating to the MANUFACTURING of
PRODUCT(S), including but not limited to the current Good Manufacturing Practices as
specified in the United States Code of Federal Regulations and all applicable rules,
regulations, orders and guidance published thereunder, the principles and guidelines of Good
Manufacturing Practices for medicinal products for human consumption as defined within EC
Directive 2003/94/EC and the associated EC Guide to Good Manufacturing Practice and any
other applicable laws, guidelines and/or regulations, in each case, as amended. The term
“cGMPs” shall not include any non-U.S. or non-CE Mark laws, guidelines and/or regulations
unless agreed to by AMP or otherwise expressly stated in the immediately preceding sentence.
	 
	 	1.9	 	The term “CONFIDENTIALITY AGREEMENT” means the Mutual Confidentiality Agreement, dated as
of August 22nd, 2008, by and between the parties hereto.
	 
	 	1.10	 	The term “CUSTOMER EQUIPMENT” means the equipment and machinery which is owned or leased
by CUSTOMER and will be used by AMP for the sole purpose of enabling AMP to MANUFACTURE
PRODUCT(S), and is described in ATTACHMENT 1.10, as such attachment may be modified from
time to time by CUSTOMER and agreed to by AMP (such agreement not to be unreasonably
withheld or delayed).
	 
	 	1.11	 	The term “CUSTOMER HOLD” means the storage of CUSTOMER owned AMP released PRODUCT(S) at
the FACILITY, and in compliance with the storage conditions as defined in the MASTER BATCH
RECORD. PRODUCT(S) will be held for a maximum of 45 days in CUSTOMER HOLD, pending release
to DELIVER PRODUCT(S) by CUSTOMER. Should release not be received for a reason other than
the failure of the PRODUCT(S) to meet the SPECIFICATIONS or failure of AMP to MANUFACTURE
the PRODUCT(S) in accordance with cGMPs, the REGULATIONS or the QUALITY AGREEMENT, AMP will
schedule shipment on behalf of CUSTOMER and DELIVER the PRODUCT to the single site
designated by CUSTOMER in writing.
	 
	 	1.12	 	The term “DELIVERY/DELIVER/DELIVERED” means delivery of PRODUCT(S) to the single site
designated by CUSTOMER in writing, EXWorks (INCOTERMS 2000), with trucking / transportation
arranged by CUSTOMER from such single site to the customer delivery point.
	 
	 	1.13	 	The term “FACILITY” means AMP’s facility located at 9342 Jeronimo Rd., Irvine, CA 92618,
or other location as mutually agreed to by both parties in writing.
	 
	 	1.14	 	The term “FDA” means the United States Food and Drug Administration and any successor
AGENCY having substantially the same function.
	 
	 	1.15	 	The term “FEE” shall have the meaning set forth in Section 6.1 of the AGREEMENT.
	 
	 	1.16	 	The term “FIRM ORDER” means a binding commitment in writing, including a requested
delivery date, made by CUSTOMER to purchase a specified amount of PRODUCT(S) MANUFACTURED by
AMP.
	 
	 	1.17	 	The term “KNOW-HOW” means information, materials and data in any form, that CUSTOMER has
determined to be necessary or helpful to MANUFACTURE PRODUCT(S), whenever and as disclosed
to AMP, as the same may be modified from time to time by CUSTOMER in its sole discretion.
Such KNOW-HOW shall not include any patents, trade secrets, formulae, processes or other
intellectual property that is used by AMP in connection with the development and
manufacturing services provided under this Agreement, but that (i) was not disclosed to AMP
by or on behalf of CUSTOMER and (ii) was not an AMP WORK FOR HIRE (collectively, “AMP
INTELLECTUAL PROPERTY”).
	 
	 	1.18	 	The term “MANUFACTURE / MANUFACTURING / MANUFACTURED” means all operations performed by
or on behalf of AMP in the receipt of MATERIALS and the production (including, without
limitation, sterilization), packaging, labeling, handling, warehousing, quality control
testing and stability testing of PRODUCT(S).

- 3 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	1.19	 	The term “MASTER BATCH RECORD” means the production batch record, developed by AMP from
the KNOW-HOW and approved by CUSTOMER in writing for use in MANUFACTURING the PRODUCT(S).
For purposes of clarity, the MASTER BATCH RECORD may contain AMP INTELLECTUAL PROPERTY.
	 
	 	1.20	 	The term “MATERIALS” means all raw materials, substance(s), components, and other items
necessary for the MANUFACTURING of PRODUCT(S).
	 
	 	1.21	 	The term “PRODUCT(S)” means the prescription pharmaceutical products in the dosage forms
listed under the heading “PRODUCT(S)” in ATTACHMENT 1.21, in finished MANUFACTURED form as
described in the MASTER BATCH RECORD.
	 
	 	1.22	 	The term “QUALITY AGREEMENT” means the Quality and Technical Agreement agreed to by and
between the parties hereto in writing.
	 
	 	1.23	 	The term “QUARTER(s)” means the period of three consecutive calendar months ending March
31, June 30, September 30 and December 31.
	 
	 	1.24	 	The term “REGULATIONS” means all laws and regulations relating to the MANUFACTURING of
PRODUCT(S), including but not limited to the current Good Manufacturing Practices as
specified in the United States Code of Federal Regulations (and all applicable rules,
regulations, orders and guidance published thereunder), FDA Quality System Regulations (and
all applicable rules, regulations, orders and guidance published thereunder), standards
established by the International Organization for Standardization (ISO), the principles and
guidelines of Good Manufacturing Practices for medicinal products for human consumption as
defined within EC Directive 2003/94/EC and the associated EC Guide to Good Manufacturing
Practice, and any other applicable laws, guidelines and/or regulations, in each case, as
amended. The term “REGULATIONS” shall not include any non-U.S. or non-CE Mark laws,
guidelines and/or regulations unless agreed to by AMP or otherwise expressly stated in the
immediately preceding sentence.
	 
	 	1.25	 	The term “SHIP / SHIPMENT” means the release of PRODUCT from AMP’s QA department to
CUSTOMER HOLD pending release by CUSTOMER to DELIVER the batch.
	 
	 	1.26	 	The term “SPECIFICATIONS” means the specifications for the PRODUCT(S) as defined in the
MASTER BATCH RECORD, as they may be modified from time to time by CUSTOMER pursuant to
Sections 4.3, 12.5 and/or 12.6.
	 
	 	1.27	 	The term “STARTUP ACTIVITIES & EQUIPMENT” means the equipment & services provided by AMP
to develop and validate the MANUFACTURING process as derived from the KNOW-HOW, as described
in more detail in ATTACHMENT 1.27.
	 
	 	1.28	 	The term “TERM” shall be as defined in Article 17.

2.0 SCOPE OF WORK; INTELLECTUAL PROPERTY

	 	2.1	 	CUSTOMER hereby appoints AMP to provide the STARTUP ACTIVITIES & EQUIPMENT and
MANUFACTURING processes for the PRODUCT(S) and MANUFACTURE PRODUCT(S) at the FACILITY
subject to and in accordance with the terms and conditions set forth in this AGREEMENT. AMP
hereby accepts such appointment to perform and provide the STARTUP ACTIVITIES & EQUIPMENT
and to MANUFACTURE PRODUCTS and to do such other acts as are herein authorized subject to
and in accordance with the terms and conditions set forth in this AGREEMENT. AMP has been
furnished with CUSTOMER KNOW-HOW to be used by AMP only for the MANUFACTURING of PRODUCTS.
All PRODUCTS MANUFACTURED under this AGREEMENT shall be the exclusive property of CUSTOMER.

- 4 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	2.2	 	AMP agrees to MANUFACTURE PRODUCT(S) for CUSTOMER in accordance with the REGULATIONS and
the AGREEMENT and the QUALITY AGREEMENT and as described in the MASTER BATCH RECORD as it
may be modified from time to time in accordance with the terms and conditions of this
AGREEMENT.
	 
	 	2.3	 	AMP shall not subcontract any portion of the MANUFACTURING without CUSTOMER’s prior
written consent. Notwithstanding the foregoing, AMP may subcontract laboratory services as
is necessary. Any and all permitted subcontractors shall be subject to the terms and
conditions of this AGREEMENT as though their names were substituted in each and every
location where AMP’s name appears, and AMP shall be responsible and liable for any breaches
of this AGREEMENT by such subcontractors.
	 
	 	2.4	 	Any intellectual property of CUSTOMER not created by AMP for CUSTOMER under this
AGREEMENT, including, without limitation, the KNOW-HOW and any CUSTOMER patents, trademarks,
copyrights, trade secrets, know-how or inventions (collectively, the “CUSTOMER IP”) shall
remain the sole and exclusive property of CUSTOMER, and no right, title or interest to any
such CUSTOMER IP is granted to AMP under this AGREEMENT.
	 
	 	2.5	 	AMP hereby acknowledges, understands, and agrees that CUSTOMER shall have and retain sole
and exclusive ownership and all rights relating to any production or design of PRODUCT(S)
and improvements or modifications to the KNOW-HOW and PRODUCT(S) and all inventions, data,
developments, technology, processes, methods, improvements, information, materials,
documents, records, data, specifications, plans, schematics, designs, drawings, prototypes,
know how, goodwill and other intellectual property and other results, which are developed,
made, conceived or reduced to practice for CUSTOMER by AMP or in connection with the
KNOW-HOW or which arise from the services provided by AMP hereunder for CUSTOMER
(collectively, the “AMP WORK FOR HIRE”), and any and all improvements, modifications,
enhancements to each of the foregoing, and all other information and materials relating
thereto and the attendant intellectual property rights of any sort throughout the world,
including, without limitation, rights in any patent, copyright, trademark, trade dress and
trade name, in any related registrations and applications for registration, and in all trade
secrets and know-how and goodwill related in any manner thereto and as a result of AMP WORK
FOR HIRE (collectively, the “INTELLECTUAL PROPERTY RIGHTS”). AMP shall maintain and make
available to CUSTOMER adequate and current written records of all AMP WORK FOR HIRE, which
will be in the form of detailed notes, sketches, drawings, materials, documents, records and
any other data that will enable any other person knowledgeable in the art of the subject to
fully understand it and carry forward the work on it. AMP agrees to assign, and does hereby
assign to CUSTOMER (or if assignment is not permitted by applicable law, waives enforcement
of and grants to CUSTOMER an exclusive, irrevocable, perpetual, worldwide, fully-paid,
royalty-free license, with right to sublicense through multiple tiers of sublicenses) any
and all interest of AMP in the AMP WORK FOR HIRE (including any INTELLECTUAL PROPERTY RIGHTS
thereto).
	 
	 	2.6	 	At CUSTOMER’s request and expense, AMP will cause its employees and agents to (a)
cooperate with and assist CUSTOMER in perfecting, obtaining, maintaining, protecting,
defending and enforcing CUSTOMER’s rights in the AMP WORK FOR HIRE and any INTELLECTUAL
PROPERTY RIGHTS thereto, and (b) execute and deliver to CUSTOMER any documents or take any
other actions as CUSTOMER may reasonably request, to effect, confirm, record, perfect,
obtain, maintain, protect, defend or enforce CUSTOMER’s rights in the AMP WORK FOR HIRE and
any INTELLECTUAL PROPERTY RIGHTS thereto. CUSTOMER will reimburse AMP for any reasonable
out-of-pocket expenses actually incurred by AMP in fulfilling its obligations under Sections
2.5 and 2.6.

3.0 EQUIPMENT

	 	3.1	 	AMP agrees to ensure that all calibration and normal operating maintenance on, cleaning
of, repair to and replacement of CUSTOMER EQUIPMENT and AMP EQUIPMENT used, directly or
indirectly, to MANUFACTURE PRODUCTS, are performed as and when necessary, provided that,
within thirty (30).

- 5 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	days after receipt of appropriate documentation from AMP (including, without
limitation, an invoice), CUSTOMER shall reimburse AMP for any reasonable expense of repair
or replacement with respect to CUSTOMER EQUIPMENT only to the extent that such need for
repair or replacement does not arise from [*].

	 	3.2	 	AMP shall be responsible for validating the CUSTOMER EQUIPMENT and the AMP EQUIPMENT
(including without limitation conducting installation, operational and performance
qualification), for production, cleaning, packaging, process and any other appropriate steps
performed at the FACILITY.
	 
	 	3.3	 	Any costs or expenses directly related to bringing any CUSTOMER EQUIPMENT needed to
MANUFACTURE PRODUCT(S) into compliance with any REGULATIONS or CUSTOMER requirements at any
time shall be borne exclusively by CUSTOMER, provided that AMP obtains the prior written
approval of CUSTOMER prior to making any such changes to the CUSTOMER EQUIPMENT.
	 
	 	3.4	 	CUSTOMER shall loan the CUSTOMER EQUIPMENT to AMP solely for the purpose of MANUFACTURING
PRODUCT(S). The loan shall be coterminous with this AGREEMENT. Title to the CUSTOMER
EQUIPMENT shall remain with CUSTOMER and AMP shall not part with the CUSTOMER EQUIPMENT
except as provided in Section 3.5 below, or permit it to become subject to any legal process
or encumbrance. Upon receipt of CUSTOMER EQUIPMENT by AMP, AMP accepts all risk, of loss or
damage to CUSTOMER EQUIPMENT, other than normal wear and tear. AMP shall handle, store and
maintain CUSTOMER EQUIPMENT under proper conditions to preserve quality and prevent damage
or other loss. AMP shall maintain, service and repair all CUSTOMER EQUIPMENT, such
equipment to be returned to CUSTOMER in good working order, reasonable wear and tear
excepted, following the termination or expiration of this AGREEMENT in accordance with
Section 3.5. AMP shall mark all CUSTOMER EQUIPMENT as “Property of Alimera Sciences.”
During the term of this AGREEMENT, AMP shall maintain commercially reasonable insurance to
protect against any loss to the CUSTOMER EQUIPMENT. Such insurance shall in no way limit or
diminish AMP’s liability under this AGREEMENT.
	 
	 	3.5	 	Within thirty (30) days after the date of termination or expiration of this AGREEMENT,
CUSTOMER will arrange for the return of the CUSTOMER EQUIPMENT and shall pay all associated
reasonable packing and transportation costs. AMP shall reasonably cooperate with CUSTOMER
in its efforts to arrange for the return of the CUSTOMER EQUIPMENT. Upon CUSTOMER’S receipt
of written notice of delay in removing such equipment, AMP shall no longer be liable for any
damage or loss related to CUSTOMER EQUIPMENT, provided that (a) such written notice of delay
was not issued before the end of the thirty (30) day period following the date of
termination or expiration of this AGREEMENT, (b) AMP has reasonably cooperated with CUSTOMER
in its efforts to arrange for the return of the CUSTOMER EQUIPMENT and (c) such damage or
loss does not arise from the gross negligence or willful misconduct on the part of AMP.

4.0 SUPPLY OF MATERIALS

	 	4.1	 	CUSTOMER will supply API and Inserter System Components (as described in ATTACHMENT 4.1)
to AMP in adequate quantities to MANUFACTURE each PRODUCT in accordance with the terms and
conditions of this AGREEMENT. Within thirty (30) days following receipt of the API from
CUSTOMER’s supplier, AMP shall test the API in accordance with the testing procedures
specified in the [*] agreed to by the parties and notify CUSTOMER in writing of the results
of any such testing. AMP may not use the shipments of API until CUSTOMER has cleared in
writing such material for use. Within fifteen (15) days following receipt of the Inserter
System Components from CUSTOMER’s supplier, AMP shall (i) review the certificate of
compliance shipped with such Inserter System Components to confirm that such Inserter System
Components have been manufactured and tested in accordance with the applicable
specifications and (ii) [*] and notify CUSTOMER in writing of the results of such actions. Such API and
Inserter System Components shall remain the property of

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 6 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	CUSTOMER and shall be used by AMP only for MANUFACTURING of PRODUCT(S).

	 	4.2	 	AMP shall purchase such MATERIALS, not including API and Inserter System Components, from
CUSTOMER approved suppliers in satisfaction of AMP’s requirements for MATERIALS. AMP shall
also be responsible to handle, maintain and safely store any API and Inserter System
Components located at the FACILITY under proper conditions to preserve quality and prevent
damage or other loss. AMP shall only be responsible for any damage or loss
to such consigned MATERIALS occurring while located at the Facility as a result of [*]. AMP’s
liability under this section 4.2 for damage to consigned MATERIALS shall not exceed [*].
	 
	 	4.3	 	In the event that CUSTOMER changes any of the MATERIALS, CUSTOMER shall reimburse AMP for
the amount of inventory of the MATERIAL (other than the API and Inserter System Components)
that was purchased by AMP in accordance with the terms and conditions of this AGREEMENT and
that had to be written off as a result of such change, at AMP’s documented cost of purchase
from the suppliers plus [*] margin, provided that AMP has used commercially reasonable
efforts to return such MATERIAL to its suppliers and was unable to do so for an amount that
is less than AMP’s documented cost for such MATERIAL plus the [*] margin. Such inventory
shall be returned to CUSTOMER or destroyed, as requested by CUSTOMER, at CUSTOMER’s
reasonable expense. If AMP is able to return such MATERIAL for less than AMP’s documented
cost for such MATERIAL plus the [*] margin, then AMP shall do so, and CUSTOMER shall
reimburse AMP for the difference in cost from the original purchase to the actual credit
received for the return of such MATERIAL plus [*] margin.
	 
	 	4.4	 	In the event that MATERIALS required to MANUFACTURE the PRODUCTS are in short supply, AMP
shall notify CUSTOMER in writing of such circumstances as soon as possible, including
without limitation the underlying reasons for such shortage, proposed remedial measures, and
the date such inability is expected to end.

5.0 ESTIMATED REQUIREMENTS AND FIRM ORDERS

	 	5.1	 	AMP agrees that it shall DELIVER only against specific FIRM ORDERS.
	 
	 	5.2	 	Upon execution of this AGREEMENT, CUSTOMER will submit to AMP a forecast listing
CUSTOMER’S expected requirements for the PRODUCT(S) for the subsequent twelve (12) months,
on a monthly basis (the “Initial Forecast”). At least [*] days prior to the beginning of
each calendar month thereafter, CUSTOMER will submit subsequent rolling forecasts of its
expected requirements for the twelve (12) month period thereafter (the “Monthly Forecast”).
The first three months of each forecast shall be binding on CUSTOMER, and CUSTOMER shall
submit FIRM ORDERS for requirements equivalent to the binding portion of the forecast, and
subsequent Monthly Forecasts may not change the forecasts for such binding months without
the consent of AMP. The remaining nine (9) months of the Initial Forecast and each of the
Monthly Forecasts will not be binding on CUSTOMER, but shall represent CUSTOMER’S projected
requirements for the PRODUCTS, provided however, AMP may order a reasonable amount of
MATERIALS based on the [*] months of any such forecast taking into account factors such as
the inventory of MATERIALS currently on hand and the lead time for such MATERIALS, and to
the extent that CUSTOMER does not purchase PRODUCT(S) using such MATERIALS before the
earlier of (i) the termination or expiration of this AGREEMENT and (ii) the MATERIALS
becoming unusable in MANUFACTURING PRODUCT(S), CUSTOMER shall reimburse AMP the documented
costs of purchase of any such MATERIAL from the suppliers plus [*] margin, that is unusable
by AMP in any of its operations. AMP shall have [*] days after receipt of each Monthly
Forecast to object in writing to any portion of the Monthly Forecast not previously accepted
by AMP that it is, or will be, unable to MANUFACTURE the quantities specified. Failure to
object to such Monthly Forecasts within such time period shall be deemed to constitute
acceptance thereof.
	 
	 	5.3	 	CUSTOMER shall issue binding FIRM ORDERS for PRODUCTS for requirements to AMP by mail,
facsimile, or electronically, corresponding to the binding portion of the forecasts. Each
FIRM ORDER

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 7 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	shall contain the following information: (i) a description of the PRODUCT by part number
and revision level; (ii) the quantity of the PRODUCT to be delivered; (iii) the delivery
date or shipping schedule; and (iv) the single location to which the PRODUCT is to be
shipped. Each FIRM ORDER shall provide an order number for billing purposes.

	 	5.4	 	AMP agrees to fill such FIRM ORDERS issued by CUSTOMER to the extent they do not exceed
[*] of the quantities stated in the first binding portion of the Initial Forecast or Monthly
Forecast (as applicable) in which such month is included. For orders that are in excess of
[*], (i) AMP agrees to fill such FIRM ORDERS up to [*] of the quantities stated in the first
binding portion of the Initial Forecast or Monthly Forecast (as applicable) in which such
month is included, and (ii) AMP will notify the CUSTOMER within [*] days of AMP’s ability to
DELIVER the quantities in such FIRM ORDER in excess of [*] of the quantities stated in the
first binding portion of the Initial Forecast or Monthly Forecast (as applicable) in which
such month is included. CUSTOMER shall place FIRM ORDERS such that the scheduled delivery
date indicated in the FIRM ORDER is at least greater than or equal to the lead-time for the
particular PRODUCT (as such lead times are set forth in ATTACHMENT 1.21) from the date of
submission of the FIRM ORDER to AMP. Any FIRM ORDER Line Item that is shipped by AMP that
is within [*] of the quantity of such PRODUCT ordered by CUSTOMER shall be considered to
fulfill such FIRM ORDER Line Item, and CUSTOMER shall pay for the number of units of
PRODUCTS actually received within such range. There shall be no minimum annual purchase
requirements.
	 
	 	5.5	 	FIRM ORDERS will be made on such form of purchase order or document as CUSTOMER may
specify from time to time in writing; provided that the terms and conditions of this
AGREEMENT shall be controlling over any terms and conditions included in any FIRM ORDER.
Any term or condition of such FIRM ORDER (or any confirmation thereof or similar form) that
is different from or contrary to the terms and conditions of this AGREEMENT shall be void.

6.0 DEPOSIT, PRICE & PAYMENT TERMS

	 	6.1	 	For the MANUFACTURING of PRODUCT(S) in accordance with the terms and conditions of this
AGREEMENT, CUSTOMER shall pay AMP the MANUFACTURING fee (the “FEE”) set forth on ATTACHMENT
6.1 in accordance with the terms and conditions of this AGREEMENT.

	 	6.1.1	 	If AMP, in its sole discretion, determines it necessary to engage a third
party (including an attorney) to collect any past due monies owed to AMP and there is
no good faith dispute over the monies owed, any costs associated with the third party
involvement will be paid by the CUSTOMER. It is understood that AMP may at any time,
upon at least [*] days written notice to CUSTOMER, alter or suspend credit terms when
CUSTOMER is delinquent in payment for invoiced merchandise, provided that such
delinquency doesn’t result from a good faith dispute over the monies owed.

	 	6.2	 	AMP shall invoice CUSTOMER upon quality control release of the PRODUCT(S) by the CUSTOMER
for the FEE corresponding to the SHIPMENT. CUSTOMER shall make payment in U.S. dollars
within [*] days following receipt of the complete and accurate invoice (the “Receipt Date”).
A complete invoice is one that contains the following format requirements: “Name and Remit
to”, Address, CUSTOMER’s Purchase Order Number, Invoice Number, Invoice Date, Description of
Goods and Services, Total Invoice Amount with miscellaneous charges listed separately and
Payment Terms.
	 
	 	6.3	 	CUSTOMER hereby accepts responsibility for production losses with respect to
CUSTOMER-supplied MATERIALS for the [*], provided that such production losses do not arise
or result from the [*]. [*].

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 8 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	6.4	 	To the extent that PRODUCT(S) supplied hereunder are subject to any sales, use, value
added or any other taxes, payment of said taxes (excluding taxes based on the net income of
AMP), if any, is CUSTOMER’s responsibility.
	 
	 	6.5	 	The FEE as of the EFFECTIVE DATE is set forth in ATTACHMENT 6.1. On or after the first
anniversary of this AGREEMENT, AMP may increase the FEE for the PRODUCT(s), one time during
each subsequent calendar year by providing written notice thereof to CUSTOMER, provided that
any such increase in FEE shall be limited to any proportionate increase in the Producer
Price Index for Pharmaceutical preparations by Rx and OTC Product, Series ID:
PCU32541D32541DRX, between the date of such notice and the date which was one (1) year prior
thereto. Any such increase shall apply only to PRODUCT(s) ordered after notice of such
change to CUSTOMER or which are scheduled for delivery more than ninety (90) days after the
date of such notice. On or after December 31, 2010, AMP may increase the ANNUAL CHARGES for
the PRODUCT(s), one time during each subsequent calendar year by providing written notice
thereof to CUSTOMER, provided that any such increase in the ANNUAL CHARGES shall be limited
to any proportionate increase in the Producer Price Index for Pharmaceutical preparations by
Rx and OTC Product, Series ID: PCU32541D32541DRX, between the date of such notice and the
date which was one (1) year prior thereto.
	 
	 	6.6	 	AMP will invoice CUSTOMER for ANNUAL CHARGES as defined on ATTACHMENT 6.1 ninety (90)
days prior to the first anniversary of the first completed validation, and will invoice
CUSTOMER each subsequent year after the initial validations (each year, a “Validation Year”)
ninety (90) days prior to the subsequent anniversary of the first completed validation.
ANNUAL CHARGE invoices are due [*] days after receipt.

7.0 DELIVERY

	 	7.1	 	AMP shall effect DELIVERY only pursuant to a FIRM ORDER, and AMP shall SHIP PRODUCTS(S)
on or before the date specified in the applicable FIRM ORDER. Each container shall be
marked as to the identity of the PRODUCT(S), the quantity of PRODUCT(S), and the related
CUSTOMER product code.

8.0 STORAGE OF PRODUCT(S); WASTE

	 	8.1	 	AMP shall, in accordance with the KNOW-HOW and CUSTOMER’s instructions, maintain
adequate and segregated storage accommodations for all of the CUSTOMER MATERIALS and
PRODUCT(S). AMP shall notify CUSTOMER whenever the inventories become insufficient to
MANUFACTURE the PRODUCT to meet the DELIVERY date(s) specified on FIRM ORDERS.
	 
	 	8.2	 	AMP shall return excess MATERIALS supplied by CUSTOMER and/or paid for by CUSTOMER to
CUSTOMER upon CUSTOMER’s request. To the extent AMP has paid for any CUSTOMER supplied
MATERIALS that are being returned to CUSTOMER, CUSTOMER shall refund amounts paid by AMP to
CUSTOMER.
	 
	 	8.3	 	AMP shall, as requested by CUSTOMER, either (i) DELIVER to CUSTOMER or (ii) dispose of
all MATERIALS and PRODUCT waste generated from the MANUFACTURING of PRODUCT(S), as agreed
between the parties. All such waste will be handled as outlined in the KNOW-HOW and
CUSTOMER’s instructions. Transportation, storage, treatment and disposal of such waste
shall be the responsibility solely of AMP, and shall be in compliance with all federal,
state and local laws, rules and regulations. In the event that CUSTOMER requests AMP to
dispose of MATERIALS and PRODUCT waste, AMP shall provide a Certificate of Destruction to
CUSTOMER upon completion of disposal.

9.0 TECHNICAL/SAFETY INFORMATION

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 9 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	9.1	 	CUSTOMER shall supply AMP with any material safety data sheets relating to MATERIALS
provided by CUSTOMER. In addition, CUSTOMER shall provide to AMP any available material
information known to CUSTOMER relating to handling, safety and environmental precautions
with respect to the MATERIALS supplied by CUSTOMER to AMP. It is the sole responsibility of
AMP to communicate such information to its employees, agents, and representatives engaged in
MANUFACTURING PRODUCT(S) and furthermore AMP shall ensure that all reasonable safety and
other procedures outlined in the KNOW-HOW or otherwise provided by CUSTOMER to AMP are
followed by AMP and its employees, agents and representatives.

10.0 CUSTOMER SUPERVISION

	 	10.1	 	AMP agrees that, at CUSTOMER’s option on reasonable notice, CUSTOMER representatives
may be present during the MANUFACTURING of PRODUCT(S) for the purposes of observing
MANUFACTURING of the PRODUCT(S). Any CUSTOMER employees who are present at the FACILITY
shall comply with AMP’s site regulations and rules that are communicated to such
representatives.

11.0 REPRESENTATIONS, WARRANTIES AND COVENANTS

	 	11.1	 	AMP represents, warrants and covenants that, at all times during the TERM, it (i) is a
corporation duly organized and validly existing and in good standing under the laws of its
jurisdiction of organization, (ii) is qualified or licensed to do business and in good
standing in every jurisdiction where such qualification or licensing is required and (iii)
has the corporate power and authority to negotiate, execute, deliver and perform its
obligations under this AGREEMENT.
	 
	 	11.2	 	AMP represents, warrants and covenants that all PRODUCT(S) shall, [*], be MANUFACTURED
(i) in accordance with the SPECIFICATIONS (and all PRODUCT(S) that are delivered by AMP to
the carrier, who is responsible for DELIVERY of the PRODUCT(S) to the CUSTOMER delivery
point meet the SPECIFICATIONS), (ii) in accordance with all applicable REGULATIONS and
AGENCY requirements in effect on the day of delivery to the carrier who is responsible for
DELIVERY of the PRODUCT(S) to the CUSTOMER delivery point, (iii) in material compliance with
cGMPs and (iv) this AGREEMENT and the QUALITY AGREEMENT. Without limiting the warranty in
Section 11.2(ii), AMP represents, warrants and covenants that no PRODUCT(S) shall [*] be
adulterated or misbranded within the meaning of the U.S. Federal Food, Drug and Cosmetic Act
(the “Act”), as a result of the actions or inactions of AMP or its employees or independent
contractors. In addition, AMP represents, warrants and covenants that: (a) it will convey
good title to the PRODUCT(S), free of all liens of any kind whatsoever; (b) it and its
FACILITY are in material compliance with all laws and regulations applicable to their
operations; (c) there are no pending investigations, inquiries or litigation pertaining to
AMP or its FACILITY or, to the best of AMP’s knowledge, are any such investigations,
inquiries or litigation threatened; (d) all AMP personnel are reasonably qualified (by
education, training and experience) to properly perform their tasks under this AGREEMENT;
(e) it will not, in the performance of its obligations under this AGREEMENT, use the
services of any person debarred or suspended under 21 U.S.C. §335(a) or (b), and it does not
currently have, and represents, warrants and covenants that it will not hire, as an officer,
an employee or an independent contractor in connection with the services provided hereunder
any person who has been convicted of a felony under the laws of the United States for
conduct relating to the regulation of any drug product under the United States Federal Food,
Drug, and Cosmetic Act; (f) AMP shall maintain at all relevant times all governmental
permits, licenses, approval, and authorities to the extent required to enable it lawfully to
properly perform its services under this AGREEMENT; and (g) it will perform the services
under this AGREEMENT in a professional and workmanlike manner.

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 10 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	11.3	 	If CUSTOMER claims that a shipment of PRODUCT(S) did not, [*] meet the warranties
specified in Section 11.2(i), CUSTOMER shall notify AMP. If CUSTOMER and AMP are unable to
agree as to whether or not such PRODUCT(S) meet the SPECIFICATIONS, the parties shall
cooperate to have the PRODUCTS in dispute analyzed by an independent testing laboratory of
recognized repute selected by CUSTOMER and approved by AMP, which approval shall not be
unreasonably withheld. The results of such laboratory testing shall be final and binding on
the parties on the issue of compliance of the PRODUCTS with the SPECIFICATIONS. Such
testing shall be for the determination of financial liability only and shall not determine
releasability of PRODUCT. If the PRODUCTS are determined to meet such warranty, then
CUSTOMER shall bear the cost of the independent laboratory testing and pay the FEE with
respect to the PRODUCTS in accordance with this AGREEMENT. If the PRODUCTS are determined
not to have met such warranty, then AMP shall bear the cost of laboratory testing, and
subject to Section 6.3, AMP shall, at CUSTOMER’s election, either promptly replace the
rejected PRODUCTS, at no cost to CUSTOMER, or promptly refund to CUSTOMER the FEE paid for
such PRODUCTS, if any. Except as provided otherwise in this AGREEMENT, including, without
limitation, in Sections 6.3, 14.1, 16.1 and 18.1.1 and remedies associated with AMP’s gross
negligence or willful misconduct, the foregoing shall be CUSTOMER’s sole remedy for such
non-conforming PRODUCTS.
	 
	 	11.4	 	Any change in the test methods for PRODUCT(S) shall, in each case, comply with cGMPs and
all applicable laws, REGULATIONS and AGENCY requirements and shall be made in accordance
with Section 12.5.
	 
	 	11.5	 	THE FOREGOING WARRANTIES AND OTHER WARRANTIES IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER
EXPRESS AND IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND ANY WARRANTY OF NONINFRINGEMENT.
THERE ARE NO ORAL PROMISES, REPRESENTATIONS OR WARRANTIES COLLATERAL TO OR AFFECTING THIS
AGREEMENT OTHER THAN THE WARRANTIES IN THIS AGREEMENT.
	 
	 	11.6	 	The warranties in this Article 11, and AMP’s obligations hereunder, shall survive
inspection, test, acceptance and use of the PRODUCT(S).

12.0 QUALITY

	 	12.1	 	AMP shall MANUFACTURE and supply PRODUCT(S) in accordance with the QUALITY AGREEMENT,
in accordance with the SPECIFICATIONS, in accordance with applicable REGULATIONS and AGENCY
requirements, including, but not limited to, all applicable drug listing regulatory
requirements consistent with cGMPs, and strictly in accordance with the KNOW-HOW as it is
described in the MASTER BATCH RECORD.
	 
	 	12.2	 	To the extent any of the terms of the QUALITY AGREEMENT conflict with the terms of this
AGREEMENT, the terms of this AGREEMENT shall control.
	 
	 	12.3	 	AMP shall notify CUSTOMER immediately of any difficulty in MANUFACTURING PRODUCT(S) in
accordance with all of the terms and conditions of this AGREEMENT.
	 
	 	12.4	 	AMP shall promptly and diligently investigate the cause of any failure in MANUFACTURING
PRODUCT(S) and provide CUSTOMER with a written report summarizing the results of AMP’s
investigation within [*] week after AMP completes such investigation. AMP shall complete
any such investigation within [*] days after AMP becomes aware of such failure, unless
granted approval by CUSTOMER for a longer period, such approval not to be unreasonably
withheld.
	 
	 	12.5	 	In the event that with respect to the PRODUCT or the MANUFACTURING thereof, the
applicable REGULATIONS and AGENCY requirements require a change to any of the following:
(A) the

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 11 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	SPECIFICATIONS; (B) the MASTER BATCH RECORD; (C) the KNOW-HOW; (D) the CUSTOMER EQUIPMENT;
and (E) the process for MANUFACTURING PRODUCT(S), including, without limitation, the test
methods used for MANUFACTURING PRODUCT(S); then AMP and CUSTOMER shall, to the extent
practicable, implement such changes. To the extent that such change is directly related to
the PRODUCT or the unique MANUFACTURING techniques utilized for such PRODUCT, CUSTOMER
shall bear such increased costs plus [*] percent margin on such increased costs. In the
event that such changes result in unusable inventory of MATERIALS or in-process PRODUCTS,
CUSTOMER shall bear the costs thereof. Any change in any of the foregoing shall, in each
case, comply with cGMPs and all applicable laws, regulations and AGENCY requirements. In
the event that AMP needs to change any of the foregoing as a result of applicable
REGULATIONS or AGENCY requirements, AMP shall (i) immediately notify CUSTOMER of such
change and request CUSTOMER’s written approval of such change (such approval not to be
unreasonably withheld or delayed) and (ii) following receipt of CUSTOMER’s approval of such
change, ensure that all PRODUCT(S) MANUFACTURED following such change meets the
SPECIFICATIONS. For the sake of clarity, to the extent CUSTOMER does not consent to a
change that is needed to comply with REGULATIONS or AGENCY requirements, then AMP shall not
be deemed to be in breach of this AGREEMENT as a result thereof.

	 	12.6	 	In the event that with respect to the PRODUCT or the MANUFACTURING thereof, either party
requests a change to any of items A thru E of Section 12.5 (other than as necessary to
comply with applicable REGULATIONS or AGENCY requirements); then AMP and CUSTOMER shall
negotiate in good faith, including if agreed, allocation of expenses.
	 
	 	12.7	 	AMP shall MANUFACTURE all PRODUCT(S) at the FACILITY. MANUFACTURING of PRODUCT(S) may
not be relocated by AMP without CUSTOMER’s prior written consent.
	 
	 	12.8	 	AMP shall permit from CUSTOMER, up to [*] reasonably qualified technical specialists for
a maximum of [*] days, upon reasonable prior notice and during normal business hours, to
conduct reasonable in-depth quality assurance audits (including, but not limited to,
quality, safety and environmental) of the FACILITY. Such audits shall be conducted not more
than [*] (except as provided in Section 12.9), with reasonable effort being made to conduct
them in coordination with any audits conducted under any other agreements between the
parties, if any.
	 
	 	12.9	 	Any additional requests for quality audits by the CUSTOMER during the same CALENDAR YEAR
will be billed at the then current AMP hourly rates. In the case where CUSTOMER feels there
is a breach or violation of this AGREEMENT or a need for an additional follow up audit, the
parties agree to meet to discuss the relevance of the issue, and should AMP agree to the
follow up on the audit, (such agreement will not be unreasonably withheld or delayed), then
the audit shall not be billed to the CUSTOMER. If, however, the parties are unable to agree
on the additional quality audit following good faith discussions, then CUSTOMER may still
conduct such audit, but CUSTOMER will be billed at the then current AMP hourly rates for
AMP’s participation in such audit.
	 
	 	12.10	 	Observations and conclusions of CUSTOMER’s audits will be issued to AMP. AMP shall
provide a written response within [*] days of receipt of such observations and conclusions.
The parties will discuss such response and promptly agree on corrective action to be
implemented.
	 
	 	12.11	 	AMP shall perform, at its quality control laboratories (or at permitted subcontractors’
facilities), such quality control tests as are indicated in the MASTER BATCH RECORD, in
accordance with the test methods and procedures described by CUSTOMER. AMP shall make the
results of its quality control tests available to CUSTOMER on or before the date of SHIPMENT
of the corresponding batches of PRODUCT(S). No production batch of PRODUCT(S) shall be
released for SHIPMENT unless AMP’s tests show the PRODUCT(S) to meet the standards set forth
in the MASTER BATCH RECORD. Should any production batch fail to meet the standards set forth
in the MASTER BATCH RECORD, CUSTOMER may, at its option, investigate the cause of such
failure or require AMP to do so and provide CUSTOMER with a written report summarizing the
results of AMP’s investigations within [*] days after AMP’s discover of such failure.
CUSTOMER shall perform such confirmatory testing of PRODUCT(S) released for SHIPMENT to
CUSTOMER as CUSTOMER shall deem appropriate, which may include, but is not

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 12 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	limited to, the recommended procedures set forth in the KNOW-HOW and the SPECIFICATIONS.
CUSTOMER shall advise AMP of any failure of such PRODUCT(S) to meet the standards set forth
in MASTER BATCH RECORD of which it is aware without undue delay.

	 	12.12	 	Should any production batch fail to meet the SPECIFICATIONS as defined in MASTER BATCH
RECORD, or was not manufactured in accordance with cGMPs or the REGULATIONS, AMP shall
immediately notify CUSTOMER in writing. Such batch shall not be DELIVERED to CUSTOMER. Any
dispute with respect to whether such batch meets the SPECIFICATIONS shall be determined in
accordance with Section 11.3 above.
	 
	 	12.13	 	AMP shall provide CUSTOMER with certificates of analysis related to PRODUCT(S) for each
batch released for SHIPMENT hereunder. These certificates will document that each batch
received by CUSTOMER conforms to the MASTER BATCH RECORD. A copy of each certificate shall
be included with each batch SHIPMENT to CUSTOMER, and one copy shall be faxed or emailed at
the same time to the CUSTOMER representative specified in the applicable FIRM ORDER.
	 
	 	12.14	 	AMP shall immediately notify CUSTOMER of any information AMP receives regarding any
threatened or pending action by any AGENCY directly related to the PRODUCT(S), including
without limitation any AGENCY non-approval or regulatory action. Upon receipt of any such
information, AMP shall promptly provide a copy of such information to CUSTOMER and
diligently consult with CUSTOMER in good faith in an effort to arrive at a mutually
acceptable procedure for taking appropriate action; provided, however, that nothing
contained herein shall be construed as restricting the right of either party to make a
timely report of such matter to any AGENCY or take other action that it reasonably and in
good faith deems to be appropriate or required by applicable law or regulation.
	 
	 	12.15	 	AMP shall immediately notify CUSTOMER of any information of which it is aware concerning
PRODUCT(S) supplied to CUSTOMER which may affect the safety or efficacy claims or the
continued marketing of the PRODUCT(S). Any such notification will include all related
information in detail. Upon receipt of any such information, AMP shall diligently consult
with CUSTOMER in good faith in an effort to arrive at a mutually acceptable procedure for
taking appropriate action; provided, however, that nothing contained herein shall be
construed as restricting the right of either party to make a timely report of such matter to
any AGENCY or take action that it reasonably and in good faith deems to be appropriate or
required by applicable law or regulation. Each party will notify the other immediately of
any health hazards with respect to PRODUCT(S) which may impact the health of employees
involved in the MANUFACTURING of PRODUCT(S).
	 
	 	12.16	 	AMP shall immediately notify CUSTOMER of any complaints received by AMP concerning
PRODUCT(S). AMP shall investigate complaints as requested by CUSTOMER and shall take
corrective action to avoid future occurrences.
	 
	 	12.17	 	AMP hereby agrees to advise CUSTOMER immediately of any proposed visit or inspection,
directly related to the PRODUCT, by any governmental authority, including, without
limitation, any AGENCY or any environmental regulatory authority, and if not prohibited by
applicable law or regulation, agrees to permit one or more reasonably qualified
representative(s) of CUSTOMER to be present if requested by CUSTOMER. AMP hereby agrees to
advise CUSTOMER as soon as practicable after the commencement of any unannounced visit or
inspection, directly related to the PRODUCT, by any governmental authority, including,
without limitation, any AGENCY or any environmental regulatory authority, and agrees to
permit one or more reasonably qualified representative(s) of CUSTOMER to be present for the
portion of the audit directly affecting CUSTOMER PRODUCT if not prohibited by applicable law
or regulation and if requested by CUSTOMER.
	 
	 	12.18	 	AMP hereby declares that as of the EFFECTIVE DATE of this AGREEMENT it is not producing,
packaging, labeling, warehousing, quality control testing (including in-process, release and
stability testing), releasing or shipping any chemical entity classified as penicillins,
alkaloids, cephalosporins, pesticides, or Beta-lactam antibiotics in the FACILITY. In the
event that AMP intends, during the TERM, to produce, package, label, warehouse, quality
control test (including in-process, release and stability

- 13 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	testing), release or ship any chemical entity belonging to the classes of products listed
above, AMP shall notify CUSTOMER in writing of its intention to do so in order to allow
CUSTOMER to consider any potential questions of cross-contamination. In the event CUSTOMER
identifies a potential problem of cross-contamination, the parties will meet to resolve the
problem.

	 	12.19	 	CUSTOMER will specify and provide AMP with press ready label artwork for all PRODUCT(S).
Artwork shall be provided in pantone color management format. AMP will comply with all
specified labeling as to each PRODUCT and each component and container and shall use only
labeling which has been approved in writing by CUSTOMER in advance. AMP shall not use
CUSTOMER labels on any products except PRODUCT(S) for which such use has been approved by
CUSTOMER. AMP shall not modify the CUSTOMER labels in any way without CUSTOMER’s prior
written consent.
	 
	 	12.20	 	AMP shall promptly provide CUSTOMER with all batch records and any investigation or
deviation reports in English related to PRODUCT(S) for each lot.

13.0 RECORDS

	 	13.1	 	AMP shall retain all records related to the (i) MANUFACTURE of PRODUCT(S) for a period
of not less than [*] years from the date of MANUFACTURE of each batch of PRODUCT(S) to which
said records pertain (such period shall be referred to as the “RETENTION PERIOD”). AMP shall
promptly provide CUSTOMER with complete and accurate copies of the appropriate documents for
each production batch, upon CUSTOMER’s request. AMP shall, at the end of the RETENTION
PERIOD, return the records to CUSTOMER. During the RETENTION PERIOD, CUSTOMER may inspect
all records related to the MANUFACTURE of PRODUCT(S) at AMP’s FACILITY during normal
business hours and with reasonable advance notice.

14.0 RECALLS

	 	14.1	 	In the event that PRODUCT(S) are recalled or withdrawn, AMP shall fully cooperate with
CUSTOMER in connection with such recall or withdrawal. If such recall or withdrawal is
caused by breach of any of the warranties set forth in Section 11.2 [*], AMP will, subject
to Section 6.3, reimburse CUSTOMER for the [*]. If such recall or withdrawal is caused by
breach of any of the warranties set forth in Section 11.2 [*], then AMP will reimburse
CUSTOMER for the [*], at CUSTOMER’s discretion. Except as provided otherwise in this
AGREEMENT, including, without limitation, in Sections 6.3, 16.1 and 18.1.1 and remedies
associated with AMP’s gross negligence or willful misconduct, [*].
	 
	 	14.2	 	AMP agrees to abide by all decisions of CUSTOMER to recall or withdraw PRODUCT(S).

15.0 COMPLIANCE WITH LAW

	 	15.1	 	AMP shall comply with and give all notices required by laws, ordinances, rules,
regulations and lawful orders of any public authority (including without limitation child
labor laws) bearing on the performance of this AGREEMENT as existing on the EFFECTIVE DATE
and as enacted or amended during the TERM. AMP shall notify CUSTOMER if it becomes aware of
any non-compliance in connection with this

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 14 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	AGREEMENT and shall take all appropriate action necessary to comply with such laws,
ordinances, rules, regulations and lawful orders.

16.0 INDEMNIFICATION

	 	16.1	 	AMP shall protect, defend, indemnify and hold CUSTOMER, its AFFILIATES and their
respective directors, officers, employees, and agents, and their respective successors and
permitted assigns, harmless from any and all third party claims, actions, causes of action,
liabilities, losses, damages, costs or expenses, including reasonable attorneys’ fees to the
extent arising out of or relating to [*]. Notwithstanding the foregoing, AMP shall not be
obligated to indemnify CUSTOMER if [*].
	 
	 	16.2	 	CUSTOMER shall protect, defend, indemnify and hold AMP, its AFFILIATES and their
respective directors, officers, employees and agents, and their respective successors and
permitted assigns, harmless from any and all third party claims, actions, causes of action,
liabilities, losses, damages, costs or expenses, including reasonable attorneys’ fees to the
extent arising out of or relate to [*].
	 
	 	16.3	 	Each party agrees to give the other (i) prompt written notice of any claims made for
which the other might be liable under the foregoing indemnification and (ii) the opportunity
to defend, negotiate, and settle such claims. The party seeking indemnification under this
AGREEMENT shall provide the other party with all information in its possession, all
authority, and all assistance necessary to enable the indemnifying party to carry on the
defense of such suit; provided, however, that each party shall have the right to retain its
own counsel to defend itself in such suit, at its own expense.
	 
	 	16.4	 	Neither party shall be responsible or bound by any settlement made without its prior
written consent, such consent not to be unreasonably withheld or delayed.

17.0 AGREEMENT TERM

	 	17.1	 	This AGREEMENT shall commence on the EFFECTIVE DATE and shall continue in full force
and effect for a period of six (6) years thereafter (the “Initial Term”), unless earlier
terminated as provided in this Agreement. This Agreement shall automatically renew for
successive one (1) year periods (each a “Renewal Term”) unless CUSTOMER or AMP delivers
written notice of non-renewal to the other party at least twelve (12) months prior to the
end of the Initial Term or any Renewal Term. As used hereinafter “TERM” shall refer to the
Initial Term and all Renewal Terms collectively.

18.0 TERMINATION

	 	18.1	 	Termination by Either Party. This AGREEMENT may be terminated by written notice given
by either party as follows:

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 15 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	18.1.1	 	If the other party shall be in breach of any of its representations, warranties,
covenants, agreements or obligations hereunder, and has not cured such breach within
sixty (60) calendar days after receipt of a notice from the non-breaching party
specifying the nature of the breach and requesting the correction of such breach (or
ten (10) business days after receipt of a notice from the non-breaching party of a
payment default and requesting the correction of such payment default). Such
termination shall be effective upon failure of the breaching party to cure such breach
within the specified time period; or
	 
	 	18.1.2	 	Upon the filing or institution of any bankruptcy, reorganization, liquidation or
receivership proceedings by the other party, or upon the failure by the other party for
more than ninety (90) days to discharge any such actions against it. Such termination
shall be effective upon receipt of the termination notice from the other party.

	 	18.2	 	Termination by CUSTOMER. This AGREEMENT may be terminated, in whole or in part,
by written notice given by CUSTOMER to AMP, effective upon receipt of the notice by AMP
(unless otherwise specified), as follows:

	 	18.2.1	 	If any required license, permit or certificate of AMP is not approved or not issued,
or is withdrawn, by any AGENCY.
	 
	 	18.2.2	 	If PRODUCT is withdrawn or deleted by CUSTOMER or by any AGENCY or any AGENCY takes
any action, or raises any objection that prevents the CUSTOMER from marketing,
distributing, importing, exporting or selling PRODUCT.

	 	18.3	 	Consequences of Termination by CUSTOMER.

	 	18.3.1	 	In the event that this AGREEMENT is terminated by CUSTOMER in accordance with SECTION
18.1, or SECTION 18.2.1, CUSTOMER shall have the right (but not the obligation) to take
DELIVERY of all PRODUCT(S) already MANUFACTURED by AMP and pay for the FEE with respect
to such PRODUCT(S) which meet the warranties set forth in this AGREEMENT; provided that
such PRODUCT(S) have been quality control released by CUSTOMER. All FIRM ORDERS shall
be cancelled and CUSTOMER shall have no further liability with respect thereto.
	 
	 	18.3.2	 	In the event that this AGREEMENT is terminated by CUSTOMER in accordance with SECTION
18.2.2, AMP (i) shall have the right to SHIP and DELIVER to CUSTOMER (and CUSTOMER shall
have the obligation to take DELIVERY of) all PRODUCT(S) already MANUFACTURED by AMP
pursuant to FIRM ORDERS and the remaining MATERIALS maintained by AMP pursuant to
SECTION 5.2 and CUSTOMER shall pay the FEE with respect to the PRODUCT(S) which meet the
warranties set forth in this AGREEMENT and the AMP documented cost of purchase from the
suppliers plus [*] margin for such remaining MATERIALS, which cannot be diverted to
AMP’s other customers’ orders and are not refundable, and (ii) shall cancel all
remaining FIRM ORDERS or [*]

	 	18.4	 	Termination by AMP. This AGREEMENT may be terminated, in whole or in part, as
follows:

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 16 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	18.4.1	 	If CUSTOMER does not commercially launch any PRODUCT listed on ATTACHMENT 1.21,
within the earlier of (i) six (6) months after receipt by CUSTOMER of FDA approval
necessary for the marketing, distribution and sale of such PRODUCT by CUSTOMER in the
United States (“FDA Approval”) or (ii) two (2) years from completion of AMP’s
validation of its processes for such PRODUCT, then AMP may terminate this AGREEMENT
with respect to such PRODUCT upon ten (10) day written notice to CUSTOMER, unless
CUSTOMER notifies AMP in writing during such ten (10) day period that in lieu of such
termination, it will (a) compensate AMP for the physical space reserved at the FACILITY
for the MANUFACTURING of such PRODUCT, [*] (the “Space Reservation Fees”) and (b)
terminate the AMP Exclusivity Obligation as defined in SECTION 22.2 with respect to
such PRODUCT. CUSTOMER will compensate AMP as described in (a) above until the earlier
of (1) it commercially launches the PRODUCT or (ii) CUSTOMER notifies AMP in writing
that AMP may go ahead and terminate this AGREEMENT for CUSTOMER’s failure to
commercially launch the applicable PRODUCT as required in this SECTION 18.4.1.
	 
	 	18.4.2	 	If CUSTOMER does not commercially launch any PRODUCT added by mutual agreement to
ATTACHMENT 1.21, within the earlier of (i) six (6) months after receipt by CUSTOMER of
FDA Approval, or two (2) years from completion of AMP’s validation of its processes for
such PRODUCT, then AMP may terminate this AGREEMENT with respect to such PRODUCT upon
ten (10) day written notice to CUSTOMER, unless CUSTOMER notifies AMP in writing during
such ten (10) day period that in lieu of such termination, it will (a) compensate AMP
for the Space Reservation Fees as defined in section 18.4.1 and (b) terminate the AMP
Exclusivity Obligation as defined in SECTION 22.2 with respect to such PRODUCT.
CUSTOMER will compensate AMP as described in (a) above until the earlier of (1) it
commercially launches the PRODUCT or (ii) CUSTOMER notifies AMP in writing that AMP may
go ahead and terminate this AGREEMENT for CUSTOMER’s failure to commercially launch the
applicable PRODUCT as required in this SECTION 18.4.2.
	 
	 	18.4.3	 	If CUSTOMER ceases commercial sale of any PRODUCT after commercial launch, then AMP
may terminate this AGREEMENT with respect to such PRODUCT by written notice given by
AMP to CUSTOMER, effective upon receipt of the notice by CUSTOMER.
	 
	 	18.4.4	 	If CUSTOMER does not purchase at least one (1) full batch of any PRODUCT during any
six (6) month period after initial commercial launch, then AMP may terminate with
respect to such PRODUCT, by written notice given by AMP to CUSTOMER, effective upon
receipt of the notice by CUSTOMER,.

	 	 	 	For the purposes of this SECTION 18.4 and 22.2, “commercially launch” and “commercial
launch” mean the orchestrated introduction of a new product to the market whereby such
product is in inventory and made available for purchase for the first time.

	 	18.5	 	Consequences of Termination by AMP. In the event that this AGREEMENT is
terminated by AMP in accordance with SECTION 18.1, AMP shall have the right to (i) DELIVER
to CUSTOMER (and CUSTOMER shall have the obligation to take DELIVERY of) all PRODUCT(S)
already MANUFACTURED by AMP pursuant to FIRM ORDERS and the remaining MATERIALS maintained
by AMP pursuant to SECTION 5 and CUSTOMER shall pay the FEE with respect to the PRODUCT(S)
which meet the warranties set forth in this AGREEMENT and AMP’S documented cost of purchase
from the suppliers plus [*] margin for such remaining MATERIALS, which cannot be diverted to
AMP’s other customers’ orders and are not refundable and (ii) either cancel all remaining
FIRM ORDERS or [*]

	 	18.6	 	No Further Liabilities. Each party understands that the rights of termination
hereunder are absolute and

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 17 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	that it has no right to a continued relationship with the other after termination,
except as expressly stated herein. Neither party shall incur any liability whatsoever for
any damage, loss or expense of any kind suffered or incurred by the other (or for any
compensation to the other) arising from or incident to any termination of this AGREEMENT
which complies with the terms of the AGREEMENT whether or not such party is aware of any
such damage, loss or expense.

	 	18.7	 	Effects of Termination. In the event of any expiration or termination of this
AGREEMENT (whether by CUSTOMER or AMP), (i) all rights, obligations and licenses of the
parties hereunder shall cease, except that (a) all obligations that accrued prior to the
effective date of expiration or termination and remedies for breach of this AGREEMENT shall
survive any expiration or termination            and (b) those obligations
specifically set forth in this ARTICLE 18.0 and those Sections specifically set forth in
ARTICLE 33.0, including, without limitation, any and all obligations to indemnify the other
party in accordance with ARTICLE 16.0 shall survive any expiration or termination of this
AGREEMENT, (ii) within [*] days after the date of termination or expiration of this
AGREEMENT, AMP will arrange for the return of the API and Inserter System Components to
CUSTOMER, and CUSTOMER shall pay all associated reasonable packing and transportation costs,
(iii) within [*] days after the date of termination or expiration of this AGREEMENT, AMP
will return all Confidential Information (as defined in the CONFIDENTIALITY AGREEMENT) to
CUSTOMER or if requested by CUSTOMER, destroy such Confidential Information and provide
written certification of such destruction signed by an authorized representative of AMP,
except that AMP shall be allowed to keep one (1) copy of the CONFIDENTIAL INFORMATION solely
for archival purposes and [*], provided that AMP continues to comply with all of its
confidentiality obligations under this AGREEMENT during the period during which such
CONFIDENTIAL INFORMATION is retained by AMP, and (iv) upon reasonable request by CUSTOMER,
AMP will [*].

19.0 INSURANCE, LIMITATION ON LIABILITY

	 	19.1	 	Unless otherwise specified in the AGREEMENT, AMP agrees to maintain, during the TERM at
its own expense, the following insurance coverage:

	 	 	 
	Commercial General Liability Insurance

	 	[*] per occurrence
	Contractual Liability

	 	[*] per occurrence
	Product Liability

	 	[*] per occurrence
	Annual Aggregate

	 	[*]

	 	19.2	 	AMP shall deliver to the CUSTOMER, prior to the execution of the AGREEMENT, Certificates
of Insurance, as evidence that policies providing such coverage and limits of insurance are
in full force and effect and with insurers with an A. M. Best rating of [*] or better.
These Certificates shall provide that not less than thirty (30) calendar days advance notice
will be given in writing to the CUSTOMER of any cancellation, termination, or material
alteration of said insurance policies.
	 
	 	19.3	 	Unless otherwise specified in the AGREEMENT, CUSTOMER agrees to maintain, during the TERM
at its own expense, the following insurance coverage:

	 	 	 
	Commercial General Liability Insurance

	 	[*] per occurrence
	Contractual Liability

	 	[*] per occurrence
	Product Liability

	 	[*] per occurrence
	Annual Aggregate

	 	[*]

	 	19.4	 	CUSTOMER shall deliver to AMP, prior to the execution of the AGREEMENT, Certificates of
Insurance, as evidence that policies providing such coverage and limits of insurance are in
full force and effect and with

	•	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 18 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	insurers with an A. M. Best rating of [*] or better. These Certificates shall provide that
not less than thirty (30) calendar days advance notice will be given in writing to AMP of
any cancellation, termination, or material alteration of said insurance policies.

	 	19.5	 	EXCEPT IN CONNECTION WITH (I) [*], (II) [*], (III) [*], (IV) [*] AND (V) TO THE EXTENT
THAT ANY EXCLUSION OR LIMITATION OF LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY
APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE UNDER OR WITH RESPECT TO THIS
AGREEMENT FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES OR LOST PROFITS
BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER
LEGAL THEORY.

	 	19.6	 	NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, IN THE EVENT THAT ANY PRODUCT DOES NOT
MEET THE LIMITED WARRANTY THEREFOR, OR AMP HAS OTHERWISE BREACHED THIS AGREEMENT, THEN THE
LIABILITY OF AMP HEREUNDER TO CUSTOMER (INCLUDING ANY LIABILITY FOR RECALL COSTS UNDER
SECTION 14 OR ANY LIABILITY UNDER THE INDEMNIFICATION PROVISIONS OF SECTION 16) SHALL NOT
EXCEED THE SUM OF (A) [*] AND (B) [*]; PROVIDED THAT, THE ABOVE LIMITATION SHALL NOT APPLY
TO (I) [*], (II) [*], (III) [*] OR (IV) TO THE EXTENT THAT ANY EXCLUSION OR LIMITATION OF
LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY APPLICABLE LAW. EXCEPT TO THE EXTENT THAT
ANY EXCLUSION OR LIMITATION OF LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY APPLICABLE
LAW, THE LIABILITY OF AMP HEREUNDER TO CUSTOMER TO THE EXTENT SUCH LIABILITY IS ATTRIBUTABLE
TO [*] SHALL NOT EXCEED [*] OF THE AMOUNTS PAID OR PAYABLE BY CUSTOMER TO AMP DURING THE [*]
MONTH PERIOD PRIOR TO THE DATE THE CAUSE OF ACTION AROSE. NOTWITHSTANDING ANYTHING HEREIN
TO THE CONTRARY, IN THE EVENT THAT CUSTOMER HAS BREACHED THIS AGREEMENT, THEN THE LIABILITY
OF CUSTOMER HEREUNDER TO AMP SHALL NOT EXCEED THE AMOUNTS PAID OR PAYABLE BY CUSTOMER TO AMP
DURING THE [*] MONTH PERIOD PRIOR TO THE DATE THE CAUSE OF ACTION AROSE; PROVIDED THAT, THE
ABOVE LIMITATION SHALL NOT APPLY TO (I) [*], (II) [*], (III) [*], (IV) [*] OR (VI) TO THE
EXTENT THAT ANY EXCLUSION OR LIMITATION OF LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY
APPLICABLE LAW. EXCEPT TO THE EXTENT THAT ANY EXCLUSION OR LIMITATION OF LIABILITY IS VOID,
PROHIBITED OR UNENFORCEABLE BY APPLICABLE LAW, THE LIABILITY OF CUSTOMER HEREUNDER TO AMP TO
THE EXTENT SUCH LIABILITY IS ATTRIBUTABLE TO [*] SHALL NOT EXCEED [*] THE AMOUNTS PAID OR
PAYABLE BY CUSTOMER TO AMP DURING THE [*] PERIOD PRIOR TO THE DATE THE CAUSE OF ACTION
AROSE.

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 19 -

 

CONFIDENTIAL TREATMENT REQUESTED

20.0 CHOICE OF FORUM

	 	20.1	 	Subject to the arbitration provisions of Section 21 below, the parties agree that the
venue for any action, injunctive application or dispute determinable by a court of law
arising out of this AGREEMENT shall be the State of New York without regard to the conflicts
of laws provisions thereof.

21.0 ARBITRATION

	 	21.1	 	The parties recognize that disputes as to certain matters may from time to time arise
which relate to either party’s rights and/or obligations hereunder. It is the objective of
the parties to establish procedures to facilitate the resolution of such disputes in an
expedient manner by mutual cooperation and without resort to litigation. To accomplish this
objective, the parties agree to follow the procedures set forth below if and when such a
dispute arises between the parties.
	 
	 	21.2	 	If any dispute arises between the parties relating to the interpretation, breach or
performance of this AGREEMENT upon request of either party, the parties agree to hold a
meeting, attended by the Chief Executive Officer or President of each party, or their
executive level designees, to attempt in good faith to negotiate a resolution of the dispute
prior to pursuing other available remedies. If, within twenty (20) days after such written
request, the parties have not succeeded in negotiating a resolution of the dispute, such
dispute shall be submitted by either party for mediation and final and binding arbitration
under the then current commercial rules and regulations of the Judicial Arbitration and
Mediation Services (“JAMS”). The mediation/arbitration proceedings shall be held in New
York, NY. Mediation shall be before a single mediator (who shall be a retired judge)
selected by mutual agreement of the parties. If not selected within 10 business days of the
notice for mediation, JAMS shall provide a list of 3 names and each party may strike one.
If not resolved by mediation then the dispute shall be resolved by binding arbitration
through JAMS and if the dispute involves a claim for damages in excess of $250,000 such
arbitration shall be before 3 arbitrators. Each party shall each select one arbitrator from
the list of available retired judges provided by JAMS, and shall mutually agree upon the
third arbitrator. If they are unable to agree on the third arbitrator, JAMS will provide a
list of three available retired judges, and each party may strike one and the remaining
judge will serve as the third arbitrator. Punitive or exemplary damages will not be
permitted under any circumstances. Judgment upon the award rendered by the arbitrators will
be final and binding on the parties and may be entered in any court having jurisdiction.
Each party shall initially bear its own costs and legal fees associated with such
arbitration. The prevailing party in any such arbitration shall be entitled to recover from
the other party the reasonable attorney’s fees, costs and expenses incurred by such
prevailing party in connection with such arbitration. The decision of the arbitrator shall
be final and binding on the parties. Judgment on the award may be entered in any court
having competent jurisdiction thereof and shall be enforceable under the Federal Arbitration
Act. Notwithstanding Sections 21.1 and 21.2, neither party shall be prohibited from seeking
injunctive or other equitable relief in any court of competent jurisdiction (including,
without limitation, in any case where issues involving the protection or unauthorized use or
disclosure of a party’s confidential information, trade secrets or intellectual property are
involved).

22.0 EXCLUSIVITY

	 	22.1	 	This AGREEMENT shall be deemed to be an exclusive contract as follows: during the TERM,
CUSTOMER, and AFFILIATE of CUSTOMER, or any transferee or successor-in-interest to
CUSTOMER’S business that relates to this AGREEMENT or rights in the PRODUCT(s) hereby agrees
to order from AMP at least eighty percent (80%) of its total requirement in a CALENDAR YEAR
for new units of PRODUCT(s) produced to fulfill CUSTOMER’S total demand for new units of
PRODUCT(s) in the United States of America, Canada and Europe (“AMP Requirement”).
	 
	 	22.2	 	CUSTOMER may order the AMP Requirement, in whole or in part, from a third party supplier (or
manufacture the AMP Requirement, in whole or in part, itself) (i) in the event that AMP is unable
to fulfill

- 20 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	the AMP Requirement, in whole or in part, in accordance with the provisions set forth in
this AGREEMENT as a result of a force majeure event, as described in Section 27.1, [*],
(ii) in the event that AMP is currently in breach of this AGREEMENT, [*] or (iii) as
described in Section 22.3. For the sake of clarity, during those years in which CUSTOMER
orders PRODUCTS(S) from a third party supplier in accordance with the terms in this Section
22.2, then in no event shall CUSTOMER be deemed to be in breach of Section 22.1 if it does
not purchase at least eighty percent (80%) of its total requirement in a CALENDAR YEAR for
new units of PRODUCT(S) in the United States of America, Canada and Europe from AMP. AMP
shall not [*].

	 	22.3	 	Notwithstanding any other provisions of this Agreement to the contrary, if AMP fails to
supply to CUSTOMER a quantity of PRODUCT(S) that comply with the applicable manufacturing
and quality control requirements of this AGREEMENT and other provisions of this AGREEMENT
equal to at least (i) [*] of the quantity of such PRODUCT(S) ordered by CUSTOMER in
accordance with SECTION 5 hereof during any consecutive [*] day period of the TERM, or (ii)
[*] of the quantity of such PRODUCT(S) ordered by CUSTOMER in accordance with SECTION 5
during any consecutive [*] day period of the TERM, then CUSTOMER shall have the right to
manufacture itself, order or purchase from any other manufacturer, distributor or supplier,
for sale or resale or distribution by CUSTOMER, a quantity of such PRODUCT(S), and only such
quantity, equal to the [*]. For purposes of this SECTION 22.3, AMP shall be deemed to have
supplied PRODUCT(S) on the date it is available for SHIPMENT to CUSTOMER if such PRODUCT(S)
comply with the applicable manufacturing and quality control requirements of this AGREEMENT
and other provisions of this AGREEMENT.

23.0 ETHICS/CONFLICT OF INTEREST

	 	23.1	 	AMP hereby agrees that in its performance under this AGREEMENT, it shall adhere to
business practices that are in accordance with the letter and spirit of applicable laws and
ethical principles as follows:
	 
	 	23.2	 	AMP agrees that all transactions in connection with this AGREEMENT will be accurately
reflected in its books and records, and that no funds or other assets shall be paid directly
or indirectly to government officials or persons acting on their behalf for the purpose of
influencing government decisions or actions with respect to CUSTOMER’s business.
	 
	 	23.3	 	AMP further agrees to conduct its activities hereunder and its dealings with CUSTOMER,
subcontractors, and third parties so as to avoid loss or embarrassment to CUSTOMER due to
any real or apparent conflict of interest, and to require that all subcontractors comply
with such policy in connection with this AGREEMENT.

24.0 INDEPENDENT CONTRACTOR

	 	24.1	 	In the performance of AMP’s obligations under this AGREEMENT, AMP shall at all times
act as and be deemed an independent contractor. Nothing in this AGREEMENT shall be
construed to render AMP or any of its employees, agents, or officers, an employee, joint
venture, agent, or partner of CUSTOMER. AMP is not authorized to assume or create any
obligations or responsibilities, express or implied, on behalf of or in the name of
CUSTOMER. It is understood that the employees, methods, facilities, and AMP EQUIPMENT of
AMP shall at all times be under AMP’s exclusive direction and control.

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 21 -

 

CONFIDENTIAL TREATMENT REQUESTED

25.0 REPRESENTATIVES OF THE PARTIES

	 	25.1	 	CUSTOMER’s representative is [*], who may be contacted at TELEPHONE # [*], FAX # [*]
and E-MAIL [*], or such other person as notified to AMP in writing from time to time.
	 
	 	25.2	 	AMP’s representative is [*], who may be contacted at TELEPHONE # [*], FAX # [*] and
E-MAIL [*]. AMP’s representative shall be AMP’s authorized representative for all purposes
under this AGREEMENT, or such other person as notified to CUSTOMER in writing from time to
time.

26.0 NOTICES

	 	26.1	 	The term “notice” as used throughout this AGREEMENT shall mean written notice, except
where specifically provided herein to the contrary. Notice shall be delivered by (i)
certified mail, return receipt requested (or the equivalent), postage pre-paid, (ii) hand
delivery with receipt acknowledged, (iii) overnight courier service that provides a delivery
receipt to the following addresses or to such other address or person as a party may specify
by notice given in accordance with this Section, or (iv) facsimile.

If to CUSTOMER:

[*]

[*]

Alimera Sciences, Inc.

6120 Windward Parkway, Suite 290

Alpharetta, GA 30005

FAX # (678) 990-5743

If to AMP:

[*]

[*]

9342 Jeronimo Rd.

Irvine, CA 92618

FAX # (949) 454-4441

Notice given in accordance with this Section shall be deemed delivered (i) when received, or (ii)
upon refusal of receipt.

27.0 FORCE MAJEURE

	 	27.1	 	No party shall be liable for a failure or delay in performing any of its obligations
under this AGREEMENT if, but only to the extent that such failure or delay is due to causes
beyond the reasonable control of the affected party, including (i) acts of God; (ii) fire,
explosion, or unusually severe weather; (iii) war, invasion, riot or other civil unrest;
(iv) governmental laws, orders, restrictions, actions, embargoes or blockages; (v) national
or regional emergency; and (vi) injunctions, strikes, or lockouts; provided that the party
affected shall promptly notify the other in writing of the force majeure condition and shall
exert reasonable efforts to eliminate, cure or overcome any such causes and to resume
performance of its obligations as soon as possible. Notwithstanding the foregoing, if
either party is prevented or delayed in performing its obligations under this AGREEMENT on
more than (i) [*] consecutive days or (ii) [*] days in the aggregate during any [*] month
period, then the party not so affected may terminate this AGREEMENT upon written notice to
the affected party.

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 22 -

 

28.0 GOVERNING LAW

	 	28.1	 	This AGREEMENT shall be governed by and construed and enforced in accordance with the
laws of the State of New York without reference to principles of conflicts of laws.

29.0 PUBLICITY

	 	29.1	 	AMP agrees not to advertise or otherwise make known to others any information regarding
this AGREEMENT. AMP further agrees not to use or reference in any advertising, sales
promotion, press release or other communication, any CUSTOMER company or representative
name, endorsement, direct or indirect quote, code, drawing, logo, trademark, specification,
or picture without the prior written consent of CUSTOMER.
	 
	 	29.2	 	This AGREEMENT and the transactions contemplated hereby shall be considered the
confidential information of the parties. Neither party shall make, nor permit their
AFFILIATES, employees or agents to make, any public statements, including, without
limitation, any press releases, with respect to this AGREEMENT and the transactions
contemplated hereby without the prior written consent of the other party, except as
otherwise permitted in this SECTION 29.2. To the extent that either party reasonably
determines that it is required to make a filing or any other public disclosure with respect
to this AGREEMENT or the transactions contemplated hereby to comply with the requirements,
rules, laws or regulations of any applicable stock exchange, Nasdaq or any governmental or
regulatory authority or body, including, without limitation, the U.S. Securities and
Exchange Commission (the “SEC”) (collectively, the “Disclosure Obligations”), or if either
party reasonably determines that it is required to file a copy of this AGREEMENT to comply
with the Disclosure Obligations, such party shall promptly inform the other party thereof,
and prior to making any such disclosure or filing of a copy of this AGREEMENT, the parties
shall [*]. The parties shall cooperate, each at its own expense, in such filing, including,
without limitation, such confidential treatment request, and shall execute all documents
reasonably required in connection therewith. The parties will [*]. Notwithstanding
anything to the contrary in this SECTION 29.2, either party may make a filing or any other
public disclosure with respect to this AGREEMENT or the transactions contemplated hereby to
timely comply with its Disclosure Obligations, without the prior written consent or
agreement of the other party, in the event that [*]. This paragraph shall apply with
respect to the filing of a copy of this AGREEMENT or any public disclosure relating to this
AGREEMENT to comply with the Disclosure Obligations, notwithstanding the provisions of the
CONFIDENTIALITY AGREEMENT or SECTION 31.2. For the avoidance of doubt, either party may,
without the prior written consent of the other party, disclose the existence and/or terms of
this AGREEMENT in connection with any financing transaction or due diligence inquiry,
provided that such information may only be disclosed to those who have obligations of
confidentiality substantially similar to those provided herein with respect to such
information.

30.0 ASSIGNMENT

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 23 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	30.1	 	This Agreement and all of the provisions hereof shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Neither
party may assign any of its rights, liabilities or obligations hereunder without the prior
written consent of the other party and any assignment without such consent shall be void.
Notwithstanding anything to the contrary in this Section 30.1, either party may assign its
rights, liabilities and obligations hereunder without the consent of the other party, but
with written notice to the other party in connection with a sale or transfer of all or
substantially all of its business to which this Agreement relates (whether by sale of stock
or assets, merger, consolidation or otherwise) or to its AFFILIATES.

31.0 ENTIRE AGREEMENT/AMENDMENTS

	 	31.1	 	This AGREEMENT and the QUALITY AGREEMENT constitute the entire agreement between the
parties hereto and shall supersede and take the place of any and all agreements, documents,
minutes of meetings or letters concerning the subject matter hereof that may, prior to the
EFFECTIVE DATE, be in existence. Furthermore, this AGREEMENT shall supersede any and all
pre-printed terms on any purchase orders, confirmations, invoices, and other related
documents. This AGREEMENT may only be amended, or a provision thereof waived, by a
statement in writing to that effect signed by duly authorized representatives of CUSTOMER
and AMP.
	 
	 	31.2	 	Notwithstanding anything to the contrary in Section 31, the CONFIDENTIALITY AGREEMENT, as
defined in Section 1.9, shall remain in full force and effect as a separate agreement and
shall govern any and all disclosures of Confidential Information (as defined under the
CONFIDENTIALITY AGREEMENT) under this AGREEMENT, including, without limitation, disclosures
of Confidential Information in connection with any and all startup activities (as described
in more detail in ATTACHMENT 1.27) that were performed prior to the EFFECTIVE DATE of this
AGREEMENT. Notwithstanding anything to the contrary in the CONFIDENTIALITY AGREEMENT, the
parties hereby agree that (i) the obligations under the CONFIDENTIALITY AGREEMENT and in
this SECTION 31.2 shall survive for a period of [*] years from the date of termination or
expiration of this AGREEMENT, provided that such obligations shall survive and continue in
effect thereafter with respect to any Confidential Information that is a trade secret under
applicable law, (ii) each party shall be responsible and liable for any breaches of
confidentiality by its AFFILIATES and by its and its AFFILIATES’ employees and consultants
in connection with the CONFIDENTIALITY AGREEMENT or this AGREEMENT, (iii) KNOW-HOW, CUSTOMER
IP and AMP WORK FOR HIRE are the Confidential Information of CUSTOMER, (iv) CUSTOMER may
provide a copy of this AGREEMENT or otherwise disclose its terms in connection with any
financing transaction or due diligence inquiry, (v) Section 5 of the CONFIDENTIALITY
AGREEMENT is hereby deleted in its entirety and replaced with the following: “Each party
represents that it is under no obligation to any third party that would interfere with its
disclosing the above-described Confidential Information to the other party”, and (vi)
Section 3 of the CONFIDENTIALITY AGREEMENT is hereby deleted in its entirety and replaced
with the following: “Confidential Information shall not include any information that (a)
was rightfully known to the receiving party without restriction before receipt from or on
behalf of the disclosing party (provided that this exclusion does not apply to AMP WORK FOR
HIRE), (b) is rightfully disclosed to the receiving party without restriction by a third
party (provided that such third party is not disclosing such information to the receiving
party on behalf of the disclosing party), (c) is or becomes generally known to the public
without violation of this AGREEMENT by the receiving party or (d) is independently developed
by the receiving party or its employees without reliance on the disclosing party’s
Confidential Information (provided that this exclusion does not apply to AMP WORK FOR
HIRE).”

32.0 SUCCESSORS AND ASSIGNS

	 	32.1	 	The terms and conditions of this AGREEMENT shall be binding upon, and shall inure to
the benefit of, the parties hereto and their respective successors and permitted assigns.

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 24 -

 

CONFIDENTIAL TREATMENT REQUESTED

33.0 SURVIVAL OF CERTAIN PROVISIONS

	 	33.1	 	The terms, provisions, representations, warranties and covenants contained in this
AGREEMENT that by their sense and context are intended to survive the performance thereof by
either party or both parties hereunder shall so survive the completion of performance,
expiration or termination of this AGREEMENT. The insurance obligations of Section 19 shall
survive for [*] years with respect to PRODUCTS MANUFACTURED prior to termination or
expiration. Any termination or expiration of this AGREEMENT shall not prejudice any other
remedies that the parties may have under this AGREEMENT. For greater certainty, termination
or expiration of this AGREEMENT for any reason shall not affect the rights, obligations and
responsibilities of the parties pursuant to SECTIONS 1, 2.4, 2.5, 2.6, 3.5, 6.1 (only in
connection with PRODUCTS MANUFACTURED in accordance with this AGREEMENT (i) prior to
termination or expiration of this AGREEMENT or (ii) as provided in SECTION 18), 6.6 (only in
connection with the current Validation Year or prior Validation Years for which payment is
due), 8.2, 11.2, 11.3, 11.5, 11.6, 13.0, 14.0, 16.0, 18.3, 18.5, 18.6, 18.7, 19.5, 19.6,
20.0, 21.0, 25.0, 26.0, 28.0, 31.0, 33.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, 40.0 and 41.0,
all of which survive any termination or expiration.

34.0 SEVERABILITY

	 	34.1	 	If any provision of this AGREEMENT is found to be invalid, illegal or unenforceable by
a court of competent jurisdiction, the remainder of this AGREEMENT shall continue in full
force and effect, and the chief executive officers of each party shall negotiate in good
faith and diligently a valid, legal, and enforceable substitute provision that reflects the
intent of such invalid, illegal or unenforceable provision and implements the purpose of
such provision. If the parties are unable to agree upon a substitute provision within [*]
days after the applicable provision was found to be invalid, illegal or unenforceable by a
court of competent jurisdiction following good faith and diligent efforts, then either party
may terminate this AGREEMENT upon written notice to the other party if, and only if, the
invalidated provision materially and adversely affects the substantive rights of the parties
hereto. [*].

35.0 HEADINGS; ATTACHMENTS AND EXHIBITS

	 	35.1	 	The headings assigned to the articles and sections of this AGREEMENT are for
convenience only and shall not limit the scope and applicability of the articles and
sections. Each and every ATTACHMENT and EXHIBIT attached hereto is hereby incorporated
herein and made a part hereof.

36.0 NON-WAIVER

	 	36.1	 	Either party’s failure to enforce any of the terms or conditions herein or to exercise
any right or privilege, or either party’s waiver of any breach under this AGREEMENT, shall
not be construed to be a waiver of any other terms, conditions, or privileges, whether of a
similar or different type.

37.0 FURTHER ASSURANCES

	 	37.1	 	Each party agrees to execute such further papers, agreements, documents, instruments
and the like as may be necessary or desirable to effect the purpose of this AGREEMENT and to
carry out its provisions.

38.0 COUNTERPARTS

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 25 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	38.1	 	This AGREEMENT may be executed in two (2) or more counterparts, each of which shall for
all purposes be deemed an original and all of which shall constitute one and the same
instrument.

39.0 CUMULATIVE REMEDIES

	 	39.1	 	No remedy referred to in this AGREEMENT is intended to be exclusive, but each shall be
cumulative and in addition to any other remedy referred to in this AGREEMENT or otherwise
available under law or at equity.

40.0 ENGLISH LANGUAGE

	 	40.1	 	This AGREEMENT, all FIRM ORDERS hereunder, any ATTACHMENTS and EXHIBITS attached
hereto, and all reports, documents and notices required hereunder, referred to herein or
requested by CUSTOMER in connection herewith shall be written in the English language.
Except as otherwise required by applicable law, the binding version of all of the foregoing
shall be the English version.

41.0 REVIEW BY LEGAL COUNSEL

	 	41.1	 	Each of the parties agrees that it has read and had the opportunity to review this
AGREEMENT with its legal counsel. Accordingly, the rule of construction that any ambiguity
contained in this AGREEMENT shall be construed against the drafting party shall not apply.

- 26 -

 

CONFIDENTIAL TREATMENT REQUESTED

IN WITNESS WHEREOF, the parties hereto have caused this AGREEMENT to be executed by their duly
authorized representatives as of the EFFECTIVE DATE.

	 	 	 	 	 	 	 
	CUSTOMER	 	Alliance Medical Products, Inc.
	 
	 	 	 	 	 	 
	By:

	 	/s/ C. Daniel Myers
	 	By:
	 	/s/ Juan C. Valdes
	 

	 	 
	 	 	 	 
	Name:

	 	C. Daniel Myers
	 	Name:
	 	Juan C. Valdes
	 

	 	 
	 	 	 	 
	Title:

	 	President and Chief Executive Officer
	 	Title:
	 	President & CEO
	 

	 	 
	 	 	 	 

- 27 -

 

CONFIDENTIAL TREATMENT REQUESTED

ATTACHMENT 1.10 —  CUSTOMER EQUIPMENT

CUSTOMER EQUIPMENT

	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	AMP Engineering Number	 	 	Equipment Description	 	 	Manufacturer	 	 	Serial Number	 
	 	002211-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002212-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002213-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002214-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002215-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	No #

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-001

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-002

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-003

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-004

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-005

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002216-006

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	 

	 	 	[*]
	 	 	[*]	 	 	 	 
	 	002217-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002218-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002219-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002220-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002221-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002221-001

	 	 	[*]
	 	 	[*]	 	 	 	 
	 	002222-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002223-000

	 	 	[*]
	 	 	[*]	 	 	 	 
	 	002224-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002224-001

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002227-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002229-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002269-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002270-000

	 	 	[*]
	 	 	[*]	 	 	 	 
	 	No #

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 28 -

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	AMP Engineering Number	 	 	Equipment Description	 	 	Manufacturer	 	 	Serial Number	 
	 	002318-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	002331-000

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	N/A

	 	 	[*]
	 	 	[*]
	 	 	[*]	 
	 	 

	 	 	[*]	 	 	 	 	 	 	 
	 	 

	 	 	[*]	 	 	 	 	 	 	 
	 	 

	 	 	[*]	 	 	 	 	 	 	 
	 

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 29 -

 

CONFIDENTIAL TREATMENT REQUESTED

ATTACHMENT 1.21 — PRODUCT(S)

	 	 	 	 	 	 	 	 	 
	 
	 	CUSTOMER code	 	 	Description	 	 	Lead-time	 
	 	ASI-001B

	 	 	Iluvien Insert, Low Dose
	 	 	[*] days	 
	 	 
	 	 	 	 	 	 	 
	 

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

-30-

 

CONFIDENTIAL TREATMENT REQUESTED

ATTACHMENT 1.27 — STARTUP ACTIVITIES

The services provided by AMP to develop and validate the MANUFACTURING process includes the
following:

[*]

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 31 -

 

CONFIDENTIAL TREATMENT REQUESTED

ATTACHMENT 4.1 — MATERIALS

MATERIALS to be supplied by CUSTOMER

	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	CUSTOMER	 	 	 	 	 	Manufacturer /	 	 	Approximate Lead	 
	 	Item Code	 	 	Description	 	 	Supplier	 	 	Time	 
	 	077-001428

	 	 	API
	 	 	Farmabios /Byron Chemicals
	 	 	[*] weeks	 
	 	077-001483

	 	 	Needle Hub Assembly
	 	 	Avail Medical
Products, Inc.
	 	 	[*] weeks	 
	 	077-001482

	 	 	Hand Piece
	 	 	Avail Medical
Products, Inc.
	 	 	[*] weeks	 
	 

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 32 -

 

CONFIDENTIAL TREATMENT REQUESTED

ATTACHMENT 6.1

MANUFACTURING FEE

Batch Size: [*] units, Batch Price: [*]

Batch Size: [*] units, Batch Price: [*]

ANNUAL CHARGES - [*]

Gamma Quarterly Dose Audit

Annual Calibration for Scopes

	*	 	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

- 33 -exv4w1

Exhibit 4.1

FIRST SUPPLEMENTAL INDENTURE

          FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 19, 2010, by
and among Suburban Propane Partners, L.P., a Delaware limited partnership (the “Partnership”),
Suburban Energy Finance Corp., a Delaware corporation (the “Company” and together with the
Partnership, the “Issuers”), and The Bank of New York Mellon (formerly known as The Bank of New
York), as trustee (the “Trustee”), to the Indenture, dated as of December 23, 2003 (the
“Indenture”).

WITNESSETH:

          WHEREAS, the Issuers and the Trustee have heretofore executed and delivered the Indenture
providing for the issuance of 6.875% Senior Subordinated Notes due 2013 (the “Notes”) of the
Issuers;

          WHEREAS, there is currently outstanding under the Indenture $250,000,000 in aggregate
principal amount of the Notes;

          WHEREAS, Section 9.02 of the Indenture provides that the Issuers and the Trustee may, with the
written consent of the Holders (as defined in the Indenture) of at least a majority in aggregate
principal amount of the outstanding Notes, enter into a supplemental indenture for the purpose of
amending the Indenture;

          WHEREAS, the Issuers have offered to purchase for cash any and all of the outstanding Notes
upon the terms and subject to the conditions set forth in the Offer to Purchase and Consent
Solicitation Statement, dated March 9, 2010 (as the same may be amended or supplemented from time
to time, the “Statement”), and in the related Consent and Letter of Transmittal (as the same may be
amended or supplemented from time to time, and, together with the Statement, the “Offer”), from
each Holder of such Notes;

          WHEREAS, the Offer is conditioned upon, among other things, the proposed amendments and
waivers (the “Proposed Amendments”) to the Indenture set forth herein having been approved by at
least a majority in aggregate principal amount of the outstanding Notes (and a supplemental
indenture in respect thereof having been executed and delivered); provided, that such Proposed
Amendments will only become operative with respect to the Notes upon the acceptance for payment by
the Issuers of the Notes representing a majority in aggregate principal amount of the outstanding
Notes pursuant to the Offer (the “Acceptance”);

          WHEREAS, the Issuers have received and delivered to the Trustee the requisite consents to
effect the Proposed Amendments under the Indenture;

          WHEREAS, the Issuers have been authorized by resolutions of their respective Board of
Supervisors or Board of Directors, as the case may be, to enter into this Supplemental Indenture;

 

 

          WHEREAS, the Issuers have delivered to the Trustee an Officers’ Certificate (as defined in the
Indenture) as well as an Opinion of Counsel (as defined in the Indenture) to the effect that the
execution and delivery of this Supplemental Indenture by the Issuers is authorized or permitted
under the Indenture and that all conditions precedent provided for in the Indenture to the
execution and delivery of this Supplemental Indenture to be complied with by the Issuers have been
complied with; and

          WHEREAS, all other acts and proceedings required by law, by the Indenture and by the
certificate of formation or certificate of incorporation, as the case may be, and the operating
agreement or bylaws, as the case may be, of each of the Issuers to make this Supplemental Indenture
a valid and binding agreement for the purposes expressed herein, in accordance with its terms, have
been duly done and performed;

          NOW, THEREFORE, in consideration of the premises and the covenants and agreements contained
herein, and for other good and valuable consideration the receipt of which is hereby acknowledged,
and for the equal and proportionate benefit of the Holders of the Notes, the Issuers and the
Trustee hereby agree as follows:

ARTICLE ONE

Section 1.01 Definitions.

          Capitalized terms used in this Supplemental Indenture and not otherwise defined herein shall
have the meanings assigned to such terms in the Indenture.

          Section 1.01 of the Indenture is amended with respect to the Notes by deleting all definitions
of terms, and references to definitions of terms, that are used exclusively in the text of the
Indenture and in the text of the Notes that are being otherwise eliminated by this Supplemental
Indenture.

ARTICLE TWO

Section 2.01 Amendments to Table of Contents.

          The Table of Contents of the Indenture is amended by deleting the titles to Sections 3.10,
4.03, 4.05, 4.07, 4.08, 4.09, 4.10, 4.11, 4.12, 4.13, 4.15, 4.16, 4.17, 4.18, 4.19, and 4.20 in
their entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.02 Amendment of Section 3.10.

          The provisions of Section 3.10 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.03 Amendment of Section 4.03.

          The provisions of Section 4.03 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

 

 

Section 2.04 Amendment of Section 4.05.

          The provisions of Section 4.05 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.05 Amendment of Section 4.07.

          The provisions of Section 4.07 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.06 Amendment of Section 4.08.

          The provisions of Section 4.08 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.07 Amendment of Section 4.09.

          The provisions of Section 4.09 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.08 Amendment of Section 4.10.

          The provisions of Section 4.10 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.09 Amendment of Section 4.11.

          The provisions of Section 4.11 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.10 Amendment of Section 4.12.

          The provisions of Section 4.12 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.11 Amendment of Section 4.13.

          The provisions of Section 4.13 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.12 Amendment of Section 4.14.

          The provisions of Section 4.14 of the Indenture are amended by deleting the text of such
Section (other than the title thereof) in its entirety and inserting in lieu thereof the following:
“Subject to Article 5 hereof, Suburban Propane shall do or cause to be done all things necessary to
preserve and keep in full force and effect its limited partnership or corporate existence, and the
corporate, partnership or other existence of each of its Subsidiaries, in accordance with the
respective organizational documents (as the same may be amended from time to time) of Suburban
Propane or any such Subsidiary; provided, however, that Suburban

 

 

Propane shall not be required to preserve the corporate, partnership or other existence of any
of its Subsidiaries, if its Board of Supervisors shall determine that the preservation thereof is
no longer desirable in the conduct of the business of Suburban Propane and its Subsidiaries, taken
as a whole, and that the loss thereof is not adverse in any material respect to the Holders of the
Notes.”

Section 2.13 Amendment of Section 4.15.

          The provisions of Section 4.15 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.14 Amendment of Section 4.16.

          The provisions of Section 4.16 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.15 Amendment of Section 4.17.

          The provisions of Section 4.17 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.16 Amendment of Section 4.18.

          The provisions of Section 4.18 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.17 Amendment of Section 4.19.

          The provisions of Section 4.19 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.18 Amendment of Section 4.20.

          The provisions of Section 4.20 of the Indenture are amended by deleting the text of such
Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.19 Amendment of Section 5.01.

          The provisions of Section 5.01 of the Indenture are amended by deleting the text of clause (4)
and inserting in lieu thereof the phrase “[intentionally omitted]”.

Section 2.20 Amendment of Section 6.01.

          The provisions of Section 6.01 of the Indenture are amended by deleting the text of clauses
(3) through (6) from Section 6.01 and inserting in lieu thereof the phrase “[intentionally
omitted]”.

 

 

ARTICLE THREE

Section 3.01 Effectiveness of Amendments.

          This Supplemental Indenture shall be effective upon its execution and delivery by the parties
hereto. The Amendments set forth in Article Two hereof will only become operative concurrently
with the acceptance for payment of Notes validly tendered and not withdrawn at or prior to the
Consent Payment Deadline (as defined in the Statement) pursuant to the Offer therefor.

Section 3.02 Continuing Effect of Indenture.

          Except as expressly provided herein, all of the terms, provisions and conditions of the
Indenture and the Notes outstanding thereunder shall remain in full force and effect. On and after
the Acceptance, each reference in the Indenture to “the Indenture,” “this Indenture,” “hereunder,”
“hereof” or “herein” shall mean and be a reference to the Indenture as supplemented by this
Supplemental Indenture unless the context otherwise requires.

Section 3.03 Construction of Supplemental Indenture.

          This Supplemental Indenture is executed as and shall constitute an indenture supplemental to
the Indenture and shall be construed in connection with and as part of the Indenture. This
Supplemental Indenture shall be governed by and construed in accordance with the laws of the State
of New York.

Section 3.04 Trust Indenture Act Controls.

          If any provision of this Supplemental Indenture limits, qualifies or conflicts with another
provision of this Supplemental Indenture or the Indenture that is required to be included by the
Trust Indenture Act of 1939, as amended, as in force at the date this Supplemental Indenture is
executed, the provision required by said Act shall control.

Section 3.05 Trustee Disclaimer.

          The recitals contained in this Supplemental Indenture shall be taken as the statements of the
Issuers, and the Trustee assumes no responsibility for their correctness. The Trustee makes no
representations as to the validity or sufficiency of this Supplemental Indenture. All rights,
protections, privileges, indemnities and benefits granted or afforded to the Trustee under the
Indenture shall be deemed incorporated herein by this reference and shall be deemed applicable to
all actions taken, suffered or omitted by the Trustee under this Supplemental Indenture.

Section 3.06 Counterparts.

          This Supplemental Indenture may be executed in any number of counterparts, each of which so
executed shall be deemed to be an original, but all such counterparts shall together constitute but
one and the same instrument.

 

 

Section 3.07 Supplemental Indenture Forms Part of Indenture.

          This Supplemental Indenture is executed and shall be construed as an indenture supplemental to
the Indenture and, as provided in the Indenture, this Supplemental Indenture forms a part of the
Indenture for all purposes. The Indenture, as amended and supplemented by this Supplemental
Indenture, is in all respects ratified and confirmed.

Section 3.08 Headings.

          The section headings herein are for convenience only and shall not affect the construction
thereof.

Section 3.09 Severability.

          In case any provision in this Supplemental Indenture or the Notes shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

[Signature Page Follows]

 

 

          IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as
of the day and year first written above.

	 	 	 	 	 
	 	SUBURBAN ENERGY FINANCE CORP.

 	 
	 	By:  	/s/ Michael J. Dunn, Jr.
 	 
	 	 	Name:  	Michael J. Dunn, Jr. 	 
	 	 	Title:  	President 	 
	 
	 	SUBURBAN PROPANE PARTNERS, L.P.

 	 
	 	By:  	/s/ Michael J. Dunn, Jr.
 	 
	 	 	Name:  	Michael J. Dunn, Jr. 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 
	 	THE BANK OF NEW YORK MELLON,

as trustee

 	 
	 	By:  	/s/ Franca M. Ferrara
 	 
	 	 	Name:  	Franca M. Ferrara 	 
	 	 	Title:  	Senior Associate 	 
	 

[Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]